

## ORGAN PROTECTIVE MANAGEMENT OF THE BRAIN-DEAD DONOR

F. H. Saner<sup>1</sup>, I. Kavuk<sup>2</sup>, H. Lang<sup>1</sup>, A. Radtke<sup>1</sup>, A. Paul<sup>1</sup>, C. E. Broelsch<sup>1</sup>

<sup>1</sup>Klinik für Allgemein-und Transplantationchirurgie

<sup>2</sup>Klinik und Poliklinik für Neurologie

University Hospital Essen, Essen, Germany

*Abstract:* The adequate management of brain dead donors on an Intensive Care Unit (ICU) is one of the major key points for a successful transplantation of harvested organs. In addition to an invasive monitoring like in any other ICU patient these patients needs a meticulous attention to their hemodynamic. The early administration of desmopressin to treat diabetes insipidus, a differentiated use of fluid resuscitation and a distinct catecholamine support are special features of an appropriate basic treatment. The administration of corticoids has to be considered if a sufficient circulation can not be regained.

*Key words:* Brain death, intensive care of organ donors, vasopressin, hemodynamic

### INTRODUCTION

The maintenance of an appropriate intensive care treatment, after a proofed brain death, has a significant impact on graft function after transplantation. By an optimal management of the potential donor both, the number and quality of harvested organs can be improved. It could be shown that these organs have a better primary function after transplantation resulting in a faster recovery of the recipients [3, 8].

Fortunately traumatic brain injuries due to accidents are continuously declining. Thus, the number of healthy organ donors, without any comorbidities is decreasing. In spite of that the total number of harvested organ has remained nearly the same, due to the acceptance of organs of older donors [17, 52].

At the same time the number of harvested organs per donor has also increased. A careful monitoring and aggressive intensive care treatment is necessary due to the acceptance of older donors with also probable more comorbidities. A couple of possible complications during the stay on an intensive care unit (ICU) are listed in Table 1 (modified to [1]). The goal of the ICU therapy is to provide the possibility of organ donation. ICU treatment directed towards organ protection has to recognize the pathophysiologic sequels of the brain death.

The main target of this treatment is the maintenance of an optimal organ perfusion and oxygenation.

### PATHOPHYSIOLOGIC DISORDER AFTER BRAIN DEAD

The initial phase after brain death is characterized by a central neurohumoral disorder. Proinflammatory mediators are released very early. The activation of PMN granulocytes is accompanied by a release of proteases and an oxygen burst with a local cell injury [34].

Additionally a couple of cardiopulmonary changes are observed: The lungs are at risk for alveolar haemorrhage and capillary leakage with consecutive lung edema [38]. In animal trials an extended rise of endogenous catecholamines could be demonstrated [4]. The serum concentration of epinephrine and norepi-

Table 1. Complication in brain dead (modified to (1))

Hypotension	72 %
Diabetes insipidus centralis	79 %
Electrolyte disorder	75 %
Arrhythmia	65 %
Hypothermia	50 %
Pulmonary complication	39%
Coagulation disorder	5 %

Table 2. Target values of the donor. (modified due to [52])

1. MAP: 70 – 90 mmHg
2. CVP 10 – 12 mmHg
3. urine output 1- 2 ml/kg/h
4.  $paO_2 > 80$  mmHg or  $SaO_2 > 95$  %
5. regular Electrolyte – and acid/base balance
6. Hämatocrit 20 – 30 %
7. Blood sugar 100 - 150 mg/dl

#### Abbreviation:

MAP: mean arterial pressure  
 CVP: central venous pressure  
 $paO_2$ : oxygen partial pressure  
 $SaO_2$ : arterial oxygen saturation

nephrene increased nearly to 20<sup>th</sup> fold. The increased oxygen consumption is mainly caused by the increased myocardial contractility accompanied by a reduced coronary blood flow resulting in local myocardial necrosis [18, 24]. In an experimental setting these damages of the heart could be prevented by a pharmacologic  $\alpha$  and  $\beta$  blockade [49].

The second phase, shortly after the initial one, shows the characteristics of a systemic inflammatory response syndrome (SIRS) with an imbalance of proinflammatory mediators (IL 1, IL 6, TNF $\alpha$ ) and anti-inflammatory mediators (IL 10). Additionally, there is a complete loss of the central sympatho-adrenergic control. There is a peripheral vasoplegia and a declining of cardiac output (CO) and mean arterial pressure (MAP) with a consecutive reduced organ perfusion [36].

The pathophysiologic changes in the initial phase of brain death, which last about 60 minutes, have no therapeutic consequences for the donor. In contrast in phase two the effects of the SIRS determine the treatment of a brain dead donor.

### HORMONE DEFICIENCY

Brain death leads to a decline of the serum concentration of hormones produced or stored in the pituitary gland, like oxytocine, vasopressin (ADH), thyroidea stimulating hormone (TSH), adrenocorticotropic hormone (ACTH). As a consequence of this decrease the concentration of those hormones, which are produced in the target organs, e.g. cortisol, aldosterone and thyroxine reduced, too [28, 29].

### ADH DEFICIENCY

One of the main key topics for the ICU treatment in brain dead donors is the loss of the hypothalamic-pituitary hormone release. As a result of ADH deficiency a central diabetes insipidus occurs [40]. Due to ADH shortage there is a lack of water resorption in the collecting tubes of the kidneys. The patients have an excessive urine output. The urine has a low density (< 1005 g/l) and the donors suffer from a hypertonic dehydration with a high serum sodium [42]. A prolonged high serum sodium concentration (> 155 mmol/l) damages the hepatocytes with an increased rate of primary non function after transplantation.

If the urine output exceeds 5 ml/kg/h (about 500 ml/h) the use of Desmopressin (Minirin<sup>TM</sup>) is indicated. Most times a pulse dose between 0.5 – 2  $\mu$ g intravenous (i.v.) effectively reduces the urine output.

If this management fails to restore the polyuria a continuous application of vasopressin (40 – 70  $\mu$ U/kg/h) is necessary [22]. At a dose rate up to 70  $\mu$ U/kg/h vasopressin only provides anti diuretic effects. At dose rates higher than 70  $\mu$ U/kg/h an additional vasoconstrictive effect of vasopressin is observed [22]. A persistent hypernatremia has to be corrected by infusions of glucose 5%.

### THYROID HORMONE DEFICIENCY

The potential organ donor suffers from Euthyroid Sick Syndrome (ESS), like many other ICU patients.

The characteristics of ESS shows a low Triiodthyronine ( $T_3$ ) level, normal or low thyroxine ( $T_4$ ), increased reverse  $T_3$  level and a variable TSH level.

Some authors point out that a low  $T_3$  level is responsible for the impaired myocardial cell metabolism and finally for the impaired myocardial contractility [16].

In some studies [4, 8] the use of i.v.  $T_3$  is recommended. The authors suggest administration of 2- 4  $\mu$ g i.v. till an effect is observed, then to start a continuous infusion with 2  $\mu$ g/h till the end of organ harvesting [35, 37]. In some other studies [28, 39] the use of  $T_3$  could improve the cardiac function. In face of the simultaneous use of vasopressin, cortisol and insulin this effect can not clearly be attributed to  $T_3$  application only.

In 2 other studies [20, 21] the only use of  $T_3$  could improve the mean arterial pressure. In opposite to this study another clinical trial [45] showed that the use of  $T_3$  deteriorated the hemodynamic situation and led to acidosis.

In a prospective randomized trial (PRT) Goarin et al. [16] analyzed the impact of  $T_3$  (0.2  $\mu$ g/kg/h) on the hemodynamics. An improved cardiac function could not be confirmed with a trans-esophageal echocardiography. The conclusion of this study was that ESS is not the main cause for the impaired myocardial contractility. Besides this lacking effect on hemodynamic of  $T_3$  there are evidences that the use of  $T_3$  leads to intractable hypertension [27].

From this point of view the only application of thyroid hormones cannot be recommended.

### CORTISOL DEFICIENCY

After breakdown of the hypothalamic-pituitary-adrenergic axis cortisol deficiency occurs in a time dependent fashion.

A brain death associated with SIRS, with a cardiovascular failure can be prevented by early use of corticoids. The side of action is listed below:

1. Suppression of the inflammatory response [6].
2. Improvement of the Horovitz index ( $paO_2/FiO_2$ ) due to reduction of cytokine induced cell damage of the lung [12].

In septic patients the use of hydrocortisone reduces significantly the need of vasopressor support [5], and decreases the incidence of organ failure [6]. Briegel recommended as dose for hydrocortisone, first a pulsed dose of 100 mg, followed by a continuous infusion of 240 mg/die.

In a prospective randomized trial the use of high dose steroids (e.g. 100 mg Methylprednisolone) could significantly improve the Horovitz index and could increase the number of transplanted lungs (31% vs 8%) [13]. This fact is supported by Meduri et al [31], who could show a benefit of methylprednisolone on the outcome of patients with ARDS.

For an improved hemodynamic and an enhancement in organ quality a complete hormone substitution is recommended [46, 47].

Rosendale recommended the replacement of:

1. Methylprednisolone: 15 mg/kg
2. Triiodothyronine: 4 µg as pulsed dose followed by continuous infusion of 3 µg/h
3. Vasopressin: 1 U as bolus, then continuous infusion 0.5 – 4 U/h
4. Insulin: adjusted to blood glucose 100 – 150 mg/dl

Actually there is an evidence based recommendation only for cortisol and vasopressin, whereas for insulin and triiodothyronine further evaluation is warranted.

### HEMODYNAMIC

The maintenance of stable hemodynamic seems to be one of the major challenges in potential donors. The target MAP should be maintained, like any other ICU patient, above 70 mmHg [30].

The monitoring for a potential donor has to be the same like for any other ICU patient. This includes measurement of temperature, urinary output, the use of an arterial line, central venous line and large bore peripheral venous access. If this is not feasible, a 12 Fr Shaldon or 8.5 Fr Introducer should be placed in a central vein for a rapid volume replacement. Donors with advanced age or impaired myocardial contractility need a pulmonary arterial catheter (PAK) or a Pulse Contour Cardiac Output System (PiCCO-System) [56].

In addition brain dead donors are at risk for a sustained and intractable hypotension. The reasons for that are listed below:

1. Relative hypovolemia due to impaired sympathetic nervous system and vasodilation like in septic patients [25].
2. Volume deficit due to
  - a. Diuretic therapy for brain edema therapy [43]
  - b. Untreated diabetes insipidus and osmotic diuresis because of hyperglycemia [44]
3. Activating of mediator systems [56]
4. Cortisol deficiency [7, 43, 44, 53, 56].

Drug of first choice is volume. Fluid resuscitation can be done with crystalloids or with colloids. Crystalloids remain only to 25% intravascular in comparison with colloids which remain nearly to 100% intravascular. As a result of this a 4<sup>th</sup> fold volume of crystalloids in comparison to colloids has to be infused to reach the same volume effect [51].

For the maintaining of optimal oxygen providing, beside the cardiac output, the red blood count is essential. Which hematocrit would be the best for organ donors has not been investigated till now. But in recent years a restrictive transfusion regime has been established in ICU patients. Hebert et al. [19] could show that ICU patients with a restrictive transfusion protocol (transfusion trigger for Hb < 7 g/dl) in comparison with a liberal protocol (transfusion trigger Hb < 10 g/dl) had a significant lower mortality. Since a potential donor has to be regarded similar like an ICU patient this restrictive protocol could be assigned to brain dead donors, too.

The volume expansion has to be adjusted to CVP. Values of 10 -12 mmHg have to be reached. The use

of a Swan-Ganz Catheter with a target pulmonary capillary wedge pressure (PCWP) of 15 mmHg allows best control of fluid management.

If an adequate volume replacement fails to restore the MAP to 70 mmHg a vasoconstrictor is indicated. In some recent studies norepinephrine could be proofed to overcome the vasodilatation caused by the non-functioning sympathetic nervous system [44, 56].

### ACID-BASE, FLUIDS, AND ELECTROLYTES

Disorders in acid-base and electrolytes are common in brain dead patients [36, 56].

With an early and aggressive therapy of diabetes insipidus (administration of vasopressin, if urine output exceeds 7 ml/kg/h and early fluid resuscitation) a hypernatremia has to be avoided. Sustained (> 24 h) serum sodium concentration above 155 mmol/l is one of the major causes of primary non function (PNF) of transplanted livers [10]. A hypernatremia can be reversed with glucose 5 % infusion. A rapid declining of sodium concentration may produce an organ edema. For this reason a drop of sodium concentration must not exceed 5 mmol/h.

Hypokaliemia due to diabetes insipidus can produce malignant dysrhythmia, especially in older donors or in donors with coronary heart disease.

However it still has to be proven if an euglycemia (90 – 110 mg/dl) has the same benefit for quality of transplanted organs like for ICU patients, where a recent study could reduce the mortality, the morbidity, the infection rate as well as the critical illness neuropathy [54].

### VENTILATION

Only a small number of donors is recognized as lung donors (about 20%) [26, 55]. Some recent reports showed a silent aspiration soon after an acute brain injury [9, 11].

Clinical practice shows that this event is associated with a lower rate of acceptance. However, from medical point of view this activity is not always correct [9, 11].

The lung function (Horovitz index) with respect to ventilation mode, Chest X-ray or better CT scan of the chest in combination with bronchoscopy is much more crucial for a possible transplantation.

In recent years lung protective ventilation with low tidal volume and permissive hypercapnia has been established in patients with ARDS. In a prospective randomized study Amato et al. [2] showed a significant reduction of mortality with the use of protective ventilation mode and permissive hypercapnia. A follow up ARDS Network study [33] examined the impact of low tidal volume (6 ml/kg) in comparison to high tidal volume (12 ml/kg). In conclusion ARDS patients have to be ventilated with small tidal volumes, high PEEP and use of permissive hypercapnia.

Unfortunately for possible lung donors there is a lack of such data. But we have to maintain the  $paO_2 > 100$  mmHg or  $SaO_2 > 95\%$ . If a ventilation mode with PEEP 5 mbar, does not provide this target values, PEEP has to be increase first (10 -15 mbar). Increased inspired oxygen has to be avoid, because of possible atelectasis.

In a couple of uncontrolled trials the improvement of prone position on ventilation/perfusion ratio and improvement of oxygenation could be proved [41, 50].

In a prospective clinical trial [15], which included 304 patients, an improvement of oxygenation was shown, but the 10 day mortality was the same. In organ donors comparable data are deficient.

In conclusion prone position is only indicated in severe damaged lungs. But these organs will not be transplanted. There is no evidence for prone position to improve the quality for possible transplanted lungs.

#### TEMPERATURE DEREGULATION

The brain dead patient will get poikilothermal. The daily temperature oscillation is abolished. Most times there is a risk for hypothermia, which has some deleterious side effects:

#### CARDIOVASCULAR AND HEMODYNAMIC EFFECTS

The risk of arrhythmias during mild or moderate hypothermia is very low. The incidence rises when the temperature drops below 30°C. The initial arrhythmia is usually atrial fibrillation.

Initially, the induction of mild hypothermia increases myocardial oxygen demand relative to support; the mechanism is probably a hypothermia-induced increase in plasma levels of adrenaline and noradrenaline leading to an increase in cardiac output and oxygen demand [14].

#### COAGULATION

Hypothermia induces bleeding diathesis, with an increased bleeding time due to its effect on platelet count [32], platelet function [32] and the kinetics of clotting enzymes and plasminogen activator inhibitors [32].

#### COLONISATION

Evidence from clinical studies and in vitro studies show that hypothermia can impair immune function. Hypothermia inhibits the release of various pro-inflammatory cytokines [23] and suppresses chemotactic migration of leukocytes and phagocytosis [48]. Furthermore hypothermia-induced insulin resistance and hyperglycemia may further increase the risk of colonisation [54].

This is a plausible mechanism for an immunosuppressive effect of hypothermia.

In conclusion one of main topics in brain dead donors is to avoid heat loss and to keep the body temperature at 37°C. This can be reached with active warming systems (e.g. Bair-hugger™) and the use of warming systems for infusions.

#### SUMMARY

Currently, extending the boundaries of marginal donor acceptability offers the best chance of dealing with donor shortage. However, this requires an optimal ICU management of the brain dead donor.

The challenge will be an early aggressive hemodynamic management and hormonal resuscitation.

Central venous pressure (CVP) or PCWP- guided (up to CVP 10 – 12 mmHg or PCWP 15 mmHg) volume replacement and if needed in combination with vasopressors like noradrenaline is recommended. The target MAP has to be above 70 mmHg.

Early administration of vasopressin (if urine output exceeds 7 ml/kg/h) to avoid hypovolemia should be strictly done.

If volume replacement and vasopressors fail to restore the MAP above 70 mmHg, hydrocortisone infusion (pulsed dose 100 mg, than 10 mg/h) should be started.

If the intensivist is able to provide these issues, he will have a major impact on graft quality and thus on successful transplantation.

#### REFERENCES

1. Ali MW, Gelb AW (1992) Organ Donor Problems and their Management. *Can J Anaesth* 39: A 125
2. Amato MB, Barbas CS, Medeiros DM, et al. (1998) Effect of a protective-ventilation strategy on mortality in the acute respiratory distress syndrome. *N Engl J Med* 338: 347-54
3. Bhorade SM, Vigneswaran W, McCabe MA, et al. (2000) Liberalization of donor criteria may expand the donor pool without adverse consequence in lung transplantation. *J Heart Lung Transplant* 19: 1199-204
4. Bittner HB, Chen EP, Kendall SW, et al. (1997) Brain death alters cardiopulmonary hemodynamics and impairs right ventricular power reserve against an elevation of pulmonary vascular resistance. *Chest* 111: 706-11
5. Bollaert PE, Charpentier C, Levy B, et al. (1998) Reversal of late septic shock with supraphysiologic doses of hydrocortisone. *Crit Care Med* 26: 645-50
6. Briegel J, Forst H, Haller M, et al. (1999) Stress doses of hydrocortisone reverse hyperdynamic septic shock: a prospective, randomized, double-blind, single-center study. *Crit Care Med* 27: 723-32
7. Cohen J, Chernov K, Ben-Shimon O, et al. (2002) Management of the brain-dead, heart-beating potential donor. *Isr Med Assoc J* 4: 243-6
8. Darby JM, Stein K, Grenvik A, et al. (1989) Approach to management of the heartbeating 'brain dead' organ donor. *Jama* 261: 2222-8
9. Dowling RD, Williams P, Zenati M, et al. (1995) Infections and pathologic factors in the donor lung. *J Thorac Cardiovasc Surg* 109: 1263-4
10. Figueras J, Busquets J, Grande L, et al. (1996) The deleterious effect of donor high plasma sodium and extended preservation in liver transplantation. A multivariate analysis. *Transplantation* 61: 410-3
11. Fisher AJ, Dark JH, Corris PA (1998) Improving donor lung evaluation: a new approach to increase organ supply for lung transplantation. *Thorax* 53: 818-20
12. Follette D, Rudich S, Bonacci C, et al. (1999) Importance of an aggressive multidisciplinary management approach to optimize lung donor procurement. *Transplant Proc* 31: 169-70
13. Follette DM, Rudich SM, Babcock WD (1998) Improved oxygenation and increased lung donor recovery with high-dose steroid administration after brain death. *J Heart Lung Transplant* 17: 423-9
14. Frank SM, Sattipunwaycha P, Bruce SR, et al. (2003) Increased myocardial perfusion and sympathoadrenal activation during mild core hypothermia in awake humans. *Clin Sci (Lond)* 104: 503-8

15. Gattinoni L, Tognoni G, Pesenti A, et al. (2001) Effect of prone positioning on the survival of patients with acute respiratory failure. *N Engl J Med* 345: 568-73
16. Goarin JP, Cohen S, Riou B, et al. (1996) The effects of triiodothyronine on hemodynamic status and cardiac function in potential heart donors. *Anesth Analg* 83: 41-7
17. Grazi GL, Cescon M, Ravaoli M, et al. (2001) A revised consideration on the use of very aged donors for liver transplantation. *Am J Transplant* 1: 61-8
18. Halejcio-Delophont P, Siaghy EM, Devaux Y, et al. (1998) Increase in myocardial interstitial adenosine and net lactate production in brain-dead pigs: an in vivo microdialysis study. *Transplantation* 66: 1278-84
19. Hebert PC, Wells G, Blajchman MA, et al. (1999) A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. *N Engl J Med* 340: 409-17
20. Jeevanandam V, Todd B, Hellman S, et al. (1993) Use of triiodothyronine replacement therapy to reverse donor myocardial dysfunction: creating a larger donor pool. *Transplant Proc* 25: 3305-6
21. Jeevanandam V (1997) Triiodothyronine: spectrum of use in heart transplantation. *Thyroid* 7: 139-45
22. Katz K, Lawler J, Wax J, et al. (2000) Vasopressin pressor effects in critically ill children during evaluation for brain death and organ recovery. *Resuscitation* 47: 33-40
23. Kimura A, Sakurada S, Ohkuni H, et al. (2002) Moderate hypothermia delays proinflammatory cytokine production of human peripheral blood mononuclear cells. *Crit Care Med* 30: 1499-502
24. Kono T, Nishina T, Morita H, et al. (1999) Usefulness of low-dose dobutamine stress echocardiography for evaluating reversibility of brain death-induced myocardial dysfunction. *Am J Cardiol* 84: 578-82
25. Lang H, Kamler M, Herold U, et al. (2002) [Donor organ harvesting]. *Chirurg* 73: 517-35; quiz 536-7
26. Lassie P, Sztark F, Thicoipe M, et al. (1995) Donor criteria for lung transplantation: a retrospective study. *Transplant Proc* 27: 2532
27. MacLean A, Dunning J (1997) The retrieval of thoracic organs: donor assessment and management. *Br Med Bull* 53: 829-43
28. Macoviak JA, McDougall IR, Bayer MF, et al. (1987) Significance of thyroid dysfunction in human cardiac allograft procurement. *Transplantation* 43: 824-6
29. Massei R, Martini C, Parma A, et al. (1993) [Care of the organ donor: respiration and metabolism]. *Minerva Anestesiol* 59: 97-100
30. Matot I, Sprung CL (2001) Definition of sepsis. *Intensive Care Med* 27 Suppl 1: S3-9
31. Meduri GU, Tolley EA, Chrousos GP, et al. (2002) Prolonged methylprednisolone treatment suppresses systemic inflammation in patients with unresolving acute respiratory distress syndrome: evidence for inadequate endogenous glucocorticoid secretion and inflammation-induced immune cell resistance to glucocorticoids. *Am J Respir Crit Care Med* 165: 983-91
32. Michelson AD, MacGregor H, Barnard MR, et al. (1994) Reversible inhibition of human platelet activation by hypothermia in vivo and in vitro. *Thromb Haemost* 71: 633-40
33. Network, T.A.R.D.S. (2000) Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Syndrome Network. *N Engl J Med* 342: 1301-8
34. Novitzky D, Wicomb WN, Cooper DK, et al. (1986) Prevention of myocardial injury during brain death by total cardiac sympathectomy in the Chacma baboon. *Ann Thorac Surg* 41: 520-4
35. Novitzky D, Cooper DK, Morrell D, et al. (1987) Brain death, triiodothyronine depletion, and inhibition of oxidative phosphorylation: relevance to management of organ donors. *Transplant Proc* 19: 4110-1
36. Novitzky D, Cooper DK, Reichart B (1987) Hemodynamic and metabolic responses to hormonal therapy in brain-dead potential organ donors. *Transplantation* 43: 852-4
37. Novitzky D, Cooper DK, Reichart B (1987) The value of hormonal therapy in improving organ viability in the transplant donor. *Transplant Proc* 19: 2037-8
38. Novitzky D, Wicomb WN, Rose AG, et al. (1987) Pathophysiology of pulmonary edema following experimental brain death in the chacma baboon. *Ann Thorac Surg* 43: 288-94
39. Novitzky D, Cooper DK, Chaffin JS, et al. (1990) Improved cardiac allograft function following triiodothyronine therapy to both donor and recipient. *Transplantation* 49: 311-6
40. Novitzky D (1991) Triiodothyronine replacement, the euthyroid sick syndrome, and organ transplantation. *Transplant Proc* 23: 2460-2
41. Pappert D, Rossaint R, Slama K, et al. (1994) Influence of positioning on ventilation-perfusion relationships in severe adult respiratory distress syndrome. *Chest* 106: 1511-6
42. Pennefather SH, Bullock RE, Mantle D, et al. (1995) Use of low dose arginine vasopressin to support brain-dead organ donors. *Transplantation* 59: 58-62
43. Powner DJ, Darby JM (2000) Management of variations in blood pressure during care of organ donors. *Prog Transplant* 10: 25-30; quiz 31-2
44. Powner DJ, Kellum JA, Darby JM (2000) Abnormalities in fluids, electrolytes, and metabolism of organ donors. *Prog Transplant* 10: 88-94; quiz 95-6
45. Randell TT, Hockerstedt KA (1993) Triiodothyronine treatment is not indicated in brain-dead multiorgan donors: a controlled study. *Transplant Proc* 25: 1552-3
46. Rosendale JD, Kauffman HM, McBride MA, et al. (2003) Hormonal resuscitation yields more transplanted hearts, with improved early function. *Transplantation* 75: 1336-41
47. Rosendale JD, Kauffman HM, McBride MA, et al. (2003) Aggressive pharmacologic donor management results in more transplanted organs. *Transplantation* 75: 482-7
48. Salman H, Bergman M, Bessler H, et al. (2000) Hypothermia affects the phagocytic activity of rat peritoneal macrophages. *Acta Physiol Scand* 168: 431-6
49. Sebening C, Hagl C, Szabo G, et al. (1995) Cardiocirculatory effects of acutely increased intracranial pressure and subsequent brain death. *Eur J Cardiothorac Surg* 9: 360-72
50. Servillo G, Roupie E, De Robertis E, et al. (1997) Effects of ventilation in ventral decubitus position on respiratory mechanics in adult respiratory distress syndrome. *Intensive Care Med* 23: 1219-24
51. Shoemaker WC (1987) Relation of oxygen transport patterns to the pathophysiology and therapy of shock states. *Intensive Care Med* 13: 230-43
52. Smits JM, Persijn GG, van Houwelingen HC, et al. (2002) Evaluation of the Eurotransplant Senior Program. The results of the first year. *Am J Transplant* 2: 664-70
53. Spiss CK, Metnitz PH, Schafer B, et al. (1997) Management of the multi-organ donor. *Acta Anaesthesiol Scand Suppl* 111: 77-8
54. van den Berghe G, Wouters P, Weekers F, et al. (2001) Intensive insulin therapy in the critically ill patients. *N Engl J Med* 345: 1359-67
55. Weill D (2002) Donor criteria in lung transplantation: an issue revisited. *Chest* 121: 2029-31

56. Zaroff JG, Rosengard BR, Armstrong WF, et al. (2002) Consensus conference report: maximizing use of organs recovered from the cadaver donor: cardiac recommendations, March 28-29, 2001, Crystal City, Va. *Circulation* 106: 836-41

*Address for correspondence:*

Dr. med. F. Saner, DEAA  
Universitätsklinikum Essen  
Klinik und Poliklinik für  
Allgemein- und Transplantationschirurgie  
Hufelandstr. 55  
D-45122 Essen, Germany  
Tel.: +49-201-723-1177  
Fax.: +49-201-723-1196  
e-mail: fuat.saner@uni-essen.de

*Received: July 28, 2004 / Accepted: September 30, 2004*